Sugi Predict

Sugi Predict / Compounds / SCHEMBL7889079

SCHEMBL7889079

SCHEMBL7889079

CCCCCCC/C=C/CCCCCCC=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 4/20 1.00
▸ TRPV1 Q8NER1 2/20 1.00
▸ TSHR P16473 3/20 0.84
▸ TERT O14746 3/20 0.56
▸ PTPN1 P18031 3/20 0.56
▸ PPARG P37231 3/20 0.56
▸ PPARD Q03181 3/20 0.56
▸ PPARA Q07869 3/20 0.56
▸ CYP1A2 P05177 2/20 0.56
▸ MAPT P10636 2/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ BLM P54132 2/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ FABP4 P15090 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ TOP1 P11387 2/20 0.56
▸ GMNN O75496 1/20 0.56
▸ USP2 O75604 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ POLB P06746 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2734732 1.00 FAAH (1.00) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL557466 1.00 FAAH (1.00) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL7289314 1.00 FAAH (1.00) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL2734273 1.00 FAAH (1.00) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL4810143 1.00 FAAH (1.00) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL1830971 1.00 FAAH (1.00) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL4803153 1.00 FAAH (1.00) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL1301131 1.00 FAAH (1.00) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL811835 1.00 FAAH (1.00) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL336238 1.00 FAAH (1.00) FAAHTRPV1TSHRTERTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4613621-A Fatty aldehydes and acids in the treatment of neurological and inflammatory diseases HOERRMANN WILHELM (DE) 1986-09-23 — — US claimed
US-4505933-A Fatty aldehydes in the treatment of Multiple Sclerosis HOERRMANN WILHELM 1985-03-19 — — US claimed
US-4239756-A Fatty aldehydes in the therapy of arteriosclerosis HORRMANN WILHELM 1980-12-16 — — US claimed
CN-118286449-A Oligomer and oligomer conjugate 豪夫迈·罗氏有限公司 2024-07-05 — — CN disclosed
CN-112274647-B Oligomer and oligomer conjugate 豪夫迈·罗氏有限公司 2024-04-23 — — CN disclosed
US-20240084307-A1 ANTISENSE OLIGOMERS TARGETING PCSK9 ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2024-03-14 — — US disclosed
US-20240067965-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 CIVI BIOPHARMA INC (US) 2024-02-29 — — US disclosed
US-20240035032-A1 OLIGOMERS AND OLIGOMER CONJUGATES HOFFMANN-LA ROCHE INC. (US) 2024-02-01 — — US disclosed
CN-117126846-A Oligonucleotide conjugates 罗氏创新中心哥本哈根有限公司 2023-11-28 — — CN disclosed
EP-4259799-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 Civi Biopharma, Inc. (US) 2023-10-18 — — EP disclosed
CN-116897206-A Oral delivery of PCSK 9-targeting antisense conjugates 四纬生物制药股份有限公司 2023-10-17 — — CN disclosed
WO-2014118267-A1 LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES SANTARIS PHARMA A/S (DK) 2014-08-07 — — WO disclosed
WO-2014076195-A1 OLIGONUCLEOTIDE CONJUGATES SANTARIS PHARMA A/S (DK) 2014-05-22 — — WO disclosed
WO-2014076196-A1 ANTI APOB ANTISENSE CONJUGATE COMPOUNDS SANTARIS PHARMA A/S (DK) 2014-05-22 — — WO disclosed
US-20120157509-A1 GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA ARROWHEAD RESEARCH CORPORATION 2012-06-21 — — US disclosed
US-6177476-B1 ADMINISTERING A GLYCEROL ETHER COMPOUND CLARION PHARMACEUTICALS INC. 2001-01-23 — — US disclosed
US-5731354-A Treatment for the inhibition of neuro-degenerative disease states CLARION PHARMACEUTICALS INC. (US) 1998-03-24 — — US disclosed
US-4687783-A Fatty aldehydes and acids in the treatment of neurological and dermatological diseases HOERRMANN WILHELM 1987-08-18 — — US disclosed
US-4613621-A Fatty aldehydes and acids in the treatment of neurological and inflammatory diseases HOERRMANN WILHELM (DE) 1986-09-23 — — US disclosed
US-4505933-A Fatty aldehydes in the treatment of Multiple Sclerosis HOERRMANN WILHELM 1985-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067965-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 PCSK9, SCD5, PCSK7 FAAH 2710/4885TRPV1 3861/4885TSHR 3836/4885
US-20120157509-A1 GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA GALK1, GALE, GALNT6 FAAH 4334/4885TRPV1 3062/4885TSHR 1212/4885
US-20240035032-A1 OLIGOMERS AND OLIGOMER CONJUGATES HAVCR2, HCCS, APOB FAAH 4730/4885TRPV1 4756/4885TSHR 3177/4885
US-20240084307-A1 ANTISENSE OLIGOMERS TARGETING PCSK9 PCSK9, PCSK7, PCSK6 FAAH 3700/4885TRPV1 3511/4885TSHR 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.